Table 2.

Binge-eating disorder.

Binge-eating disorder
Diagnosis	Screeninga	Treatment	References
Binge-Eating Disorder (BED) is diagnosed when the patient episodically consumes large amounts of food more than once per week for at least three months, without self-induced vomiting (purging), without laxative use, and without extra physical exercise. Patients often feel a lack of self-control, shame, and guilt. Binge eating disorder occurs in approximately 3% of U.S. adults and may occur in up to 50% of patients with severe obesity.	Binge-Eating Scale Binge Eating Disorder Screener-7 (BED7)	Treatment may include cognitive behavior therapy (i.e., alteration in thinking to facilitate more healthful outcomes). Although not FDA-indicated for this use, pharmacotherapies that may be efficacious in treating binge-eating disorder include some selective serotonin reuptake inhibitors (e.g., fluoxetine, paroxetine, and sertraline) and topiramate. Paroxetine should be used with caution due to potential obesogenic effect [34]. In addition to an indication to treat attention deficit hyperactivity disorder, lisdexamfetamine dimesylate has an FDA indication to treat binge-eating disorder.b	[[35], [36], [37], [38], [39], [40], [41], [42], [43], [44]]

^aListed screening tests are beyond common general eating disorder screening tests described in the first paragraph of this section.

^bSee “Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022” for a detailed discussion of lisdexamfetamine dimesylate.